No Data
BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics
BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics
BeyondSpring Reports FY23 Loss Per Share Of $(0.54) Vs. $(0.85) Last Year
As of December 31, 2023, the Company had cash, cash equivalents, restricted cash, and short-term investments of $17.9 million.Net loss attributable to the Company was $(21.0) million for the year ende
BeyondSpring Files 2023 Annual Report on Form 20-F
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer
Press Release: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.
IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment
BeyondSpring (BYSI) said Monday that the first patient has been dosed in a phase 2 investigator-initiated trial of pembrolizumab, plinabulin plus etoposide/platinum for first-line extensive-stage smal